Cambridge Trust CO Apellis Pharmaceuticals, Inc. Transaction History
Cambridge Trust CO
- $2.6 Billion
- Q1 2024
A detailed history of Cambridge Trust CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 11,500 shares of APLS stock, worth $280,255. This represents 0.03% of its overall portfolio holdings.
Number of Shares
11,500
Previous 11,500
-0.0%
Holding current value
$280,255
Previous $688,000
1.89%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$298 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$290 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$288 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$245 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$235 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.68B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...